Document Detail


Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.
MedLine Citation:
PMID:  18949521     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of the study is to compare the tumor-specific targeting, pharmacokinetics, and biodistribution of (64)Cu-DOTA-HB22.7 when administered to xenograft-bearing mice intravenously (IV), intraperitoneally (IP), and subcutaneously (SQ). PROCEDURES: Mice bearing human non-Hodgkin's lymphoma (NHL) xenografts were injected IV, IP, or SQ with (64)Cu-DOTA-HB22.7. Xenograft targeting was evaluated by micro positron emission tomography (microPET) and confirmed by organ biodistribution studies. Blood measurements of (64)Cu were performed to determine the pharmacokinetics and clearance of (64)Cu-DOTA-HB22.7. RESULTS: (64)Cu-DOTA-HB22.7 demonstrated equivalent tumor targeting within 24-48 h, regardless of the route of administration. Organ biodistribution confirmed tumor-specific targeting. Blood pharmacokinetics demonstrated that (64)Cu-DOTA-HB22.7 accessed the bloodstream after IP and SQ administration to a similar degree as IV administration, albeit at a slower rate. CONCLUSIONS: These findings establish (64)Cu-DOTA-HB22.7 as a potential radioimmunotherapeutic and/or NHL-specific imaging agent. These findings provide evidence that IP and SQ administration can achieve results equivalent to IV administration and may lead to more efficient, reproducible treatment plans for antibody-based therapeutics.
Authors:
Shiloh M Martin; Robert T O'Donnell; David L Kukis; Craig K Abbey; Hayes McKnight; Julie L Sutcliffe; Joseph M Tuscano
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2008-10-24
Journal Detail:
Title:  Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging     Volume:  11     ISSN:  1536-1632     ISO Abbreviation:  Mol Imaging Biol     Publication Date:    2009 Mar-Apr
Date Detail:
Created Date:  2009-02-05     Completed Date:  2009-09-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101125610     Medline TA:  Mol Imaging Biol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  79-87     Citation Subset:  IM    
Affiliation:
Division of Hematology and Oncology, Department of Internal Medicine, University of California, Davis Cancer Center, Davis, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / administration & dosage,  pharmacokinetics*
Copper Radioisotopes / administration & dosage,  pharmacokinetics*
Female
Flow Cytometry
Immunoconjugates / administration & dosage,  pharmacokinetics
Injections
Lymphoma, Non-Hodgkin / drug therapy*,  radionuclide imaging*
Mice
Mice, Nude
Neoplasm Transplantation
Positron-Emission Tomography
Radiopharmaceuticals / administration & dosage,  chemical synthesis,  pharmacokinetics*
Succinimides / administration & dosage,  pharmacokinetics
Tissue Distribution
Transplantation, Heterologous
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
R24 CA110804/CA/NCI NIH HHS; R33 CA89706/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Copper Radioisotopes; 0/DOTA-NHS; 0/Immunoconjugates; 0/Radiopharmaceuticals; 0/Succinimides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance o...
Next Document:  Fracture of the Proximal Pole of the Bipartite Carpal Scaphoid: A Probable Holt-Oram-like Syndrome.